News & Events

A New Discovery

August 1st, 2023

NuChem is delighted to announce its acquisition by leading integrated drug discovery provider, Sygnature Discovery.
This acquisition cements Sygnature as one of the world’s largest players in integrated drug discovery phase solutions and advances their vision to become the global market leader.

2nd NuChem Symposium 2023

September 22, 2023

We are thrilled to announce the upcoming NuChem Sciences Symposium, a unique event designed to foster collaboration and bridge the gap between academia and industry in the field of biology and medicinal chemistry for drug discovery.

NuChem ranks 44th of the top 300 most important small and medium enterprises in Quebec

October 26, 2022

On the annual top 300 list produced by Les Affaires NuChem ranked in the top 50, and is the only Contract Research Organization (CRO) on the list, which is considered a benchmark for the entrepreneurial community.

NuChem awards for the 2nd time its industrial scholarship to two promising students

October 4, 2022

One year ago, the first industrial scholarship was awarded to three students in their final year of doctoral studies. NuChem Sciences has reiterated its commitment to the training of future scientific researchers in university by awarding this scholarship for the second time.

September 16: OmegaChem to host its first Omega Symposium

August 9, 2022

As a major employer of world-class scientific talent in the Quebec City area, OmegaChem is proud to host the first-ever Omega Symposium!

NuChem Sciences inaugurates its new laboratories and receives the Medal of the National Assembly of Quebec

July 14, 2022

NuChem’s leaders, scientists and support staff joined some 60 guests to inaugurate the world-class laboratories in Dobrin Street, Montreal.

NuChem Sciences: 10 years of accelerating drug discovery. Together.

June 20, 2022

As we celebrate the 10th anniversary of NuChem Sciences, here are the highlights of our company’s past achievements and its vision for an even brighter future.

NuChem Sciences awards scholarships to three promising students in Canadian universities

September 23, 2021

NuChem Sciences is pleased to announce a new fellowship to support and mentor three outstanding doctoral graduate students in the fields of organic synthesis or medicinal chemistry.

NuChem Sciences joins forces with OmegaChem to become Canada’s CRO focused on chemistry

September 3, 2021

We are pleased to announce that NuChem Sciences is joining forces with OmegaChem to become Canada’s CRO focused on chemistry.

Minister of labour J. Boulet visits Nuchem Sciences

August 8, 2021

We had the pleasure of hosting a visit of Mr. Jean Boulet, the Minister of Labour, Employment and Social Solidarity and Minister responsible for the Mauricie region, in our state-of-the-art laboratories to discuss with members of our teams.

NuChem Sciences announces new Discovery Partner Program™

April 15, 2021

This new service offers our team’s superior talent and our cutting-edge scientific technology, paired with responsive communication, efficiency and clarity along the drug discovery journey.

NuChem Sciences launches new brand and announces new name

April 15, 2021

After experiencing exponential growth in recent years, NuChem Therapeutics is proud to launch its new brand identity. As part of this exciting step forward, we will adopt a new corporate name: NuChem Sciences.

Universite de Montreal Journee Carriere

January 15, 2020

Our team was happy to meet and greet students at the Universite de Montreal MIL Campus as part of the Journee Carriere event.

NuChem Therapeutics Completed the Acquisition of Amplia Pharmatek

October 19, 2019

Amplia Pharmatek is an innovative service provider who specializes in Discovery Biology, in vivo Pharmacology, Pharmacokinetics and Toxicology.

Completion of a Successful Management Buyout Transaction At NuChem Therapeutics

February 22, 2019

On December 13th 2018, senior management of the company, comprised of Marc LeBel, Daniel Guay, Marc Janes and John Mancuso, acquired 95% of the voting shares from Amorchem LP, the venture capital fund which founded NuChem in 2011.